A scientific report has raised questions about how much Leqimbi and Kisunla — the “breakthrough” Alzheimer’s drugs that have hit the market in the last few years — really help slow the disease.
These Alzheimer’s drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.
Related Posts
Popular News
Latest News
SEC Outlines Crypto As Top Priority In Pro-Innovation Agenda
Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure The US Securities and Exchange Commission (SEC)...
These Alzheimer’s drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.
A scientific report has raised questions about how much Leqimbi and Kisunla — the “breakthrough” Alzheimer’s drugs that have hit...
Stablecoins Behave Like FX Markets as Liquidity Splits: Eco CEO
Stablecoins behave like a fragmented foreign exchange market, where liquidity is spread across blockchains and pools, creating price differences and...
HDFC Bank Q4 FY26 slides: deposit surge drives growth amid stability
HDFC Bank Q4 FY26 slides: deposit surge drives growth amid stability
Welcome to Global Finances Daily, your go-to source for all things finance. Our mission is to provide our readers with valuable information and insights to help them achieve their financial goals and secure their financial future.